Shanghai MicuRx Pharmaceutical Co. Ltd. A
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resi… Read more
Shanghai MicuRx Pharmaceutical Co. Ltd. A (688373) - Total Liabilities
Latest total liabilities as of June 2025: CN¥459.53 Million CNY
Based on the latest financial reports, Shanghai MicuRx Pharmaceutical Co. Ltd. A (688373) has total liabilities worth CN¥459.53 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai MicuRx Pharmaceutical Co. Ltd. A - Total Liabilities Trend (2020–2024)
This chart illustrates how Shanghai MicuRx Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai MicuRx Pharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Shanghai MicuRx Pharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Everlight Chemical Industrial Corp
TW:1711
|
Taiwan | NT$4.31 Billion |
|
First Foundation Inc.
NYSE:FFWM
|
USA | $10.99 Billion |
|
BFI Finance Indonesia Tbk
JK:BFIN
|
Indonesia | Rp14.54 Trillion |
|
TCI Co Ltd
TWO:8436
|
Taiwan | NT$4.93 Billion |
|
Newron Pharmaceuticals SpA
SW:NWRN
|
Switzerland | CHF59.81 Million |
|
Southern Sun Limited
F:JK9
|
Germany | €4.78 Billion |
|
Eco-Shop Marketing Berhad
KLSE:5337
|
Malaysia | RM800.17 Million |
|
Ningbo Daye Garden Machinery Co Ltd
SHE:300879
|
China | CN¥3.52 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Shanghai MicuRx Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai MicuRx Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai MicuRx Pharmaceutical Co. Ltd. A (2020–2024)
The table below shows the annual total liabilities of Shanghai MicuRx Pharmaceutical Co. Ltd. A from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥410.16 Million | +22.60% |
| 2023-12-31 | CN¥334.56 Million | +18.18% |
| 2022-12-31 | CN¥283.10 Million | +34.70% |
| 2021-12-31 | CN¥210.17 Million | +281.02% |
| 2020-12-31 | CN¥55.16 Million | -- |